Loading patent…
AssigneesServizo Galego De SAúDe, FundacióN PúBlica Galega Instituto De InvestigacióN Sanitaria De Santiago De Compostela, Universidade De Santiago De Compostela
InventorsRodolfo GÓMEZ BAHAMONDE, Miriam LÓPEZ FAGÚNDEZ, Eloi FRANCO TREPAT, Ana ALONSO PÉREZ, María GUILLÁN FRESCO, Andrés PAZOS PÉREZ, Alberto Agustin JORGE MORA
Estimating the term…
The present invention is focused on an in vitro method for the diagnosis or prognosis of Neurogenic Heterotopic Ossification (NHO) comprising assessing the expression level of Transforming Growth Factor Beta Induced (TGFBi) in a biological sample obtained from the subject that comprises astrocyte and/or nerve secretome. Moreover, the present invention also refers to a therapeutic strategy for treating NHO based on TGFBi inhibitors.
In vitro method for the diagnosis or prognosis of Neurogenic Heterotopic Ossification which comprises assessing the expression level of Transforming Growth Factor Beta Induced (TGFBi) in a biological sample obtained from the subject that comprises astrocyte and/or nerve secretome, wherein the determination of an increase of the expression level of TGFBi with respect to a pre-established expression level measured in healthy control subjects, is an indication that the subject may be suffering from Neurogenic Heterotopic Ossification or has a poor prognosis.
In vitro use of TGFBi in a biological sample obtained from the subject that comprises astrocyte or nerve secretome for the diagnosis or prognosis of Neurogenic Heterotopic Ossification.
In vitro use of a kit comprising reagents for the determination of the level of expression of TGFBi in a biological sample obtained from the subject that comprises astrocyte or nerve secretome for the diagnosis or prognosis of Neurogenic Heterotopic Ossification.
TGFBi inhibitors for use in the treatment of Neurogenic Heterotopic Ossification, characterized in that the method comprises the inhibition of TGFBi in astrocytes and/or nerve secretome and wherein the inhibitor is selected from:
An in vitro method for identifying compounds for the treatment of Neurogenic Heterotopic Ossification, which comprises a) determining if the inhibition of TGFBi in astrocyte and/or nerve secretome, or the elimination of the anabolic effects of astrocytes on osteoblasts has taken place, by the candidate compound, and b) wherein if said inhibition of TGFBi or the elimination of the anabolic effects of astrocytes on osteoblasts has taken place, it is indicative of the candidate may be effective in the treatment of Neurogenic Heterotopic Ossification.
Dependencies are inferred from the claim text.